These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9372093)

  • 1. Detection of minimal residual disease in acute and chronic leukemias.
    Radich J
    Curr Opin Hematol; 1996 Jul; 3(4):310-4. PubMed ID: 9372093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal residual disease.
    Radich J
    Curr Opin Hematol; 1995 Jul; 2(4):300-4. PubMed ID: 9372011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of minimal residual disease.
    Dölken G
    Adv Cancer Res; 2001; 82():133-85. PubMed ID: 11447762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the detection of minimal residual disease.
    Radich J; Thomson B
    Curr Opin Hematol; 1997 Jul; 4(4):242-7. PubMed ID: 9260051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of minimal residual disease in leukemia detected by polymerase chain reaction: is molecular remission a milestone for achieving a cure?
    Ito Y; Miyamura K
    Leuk Lymphoma; 1994 Dec; 16(1-2):57-64. PubMed ID: 7696932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of minimal residual disease in acute myelogenous leukemia.
    Raanani P; Ben-Bassat I
    Acta Haematol; 2004; 112(1-2):40-54. PubMed ID: 15179004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease studies in acute leukemia.
    Campana D
    Am J Clin Pathol; 2004 Dec; 122 Suppl():S47-57. PubMed ID: 15690642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of minimal residual disease in leukemia.
    Faderl S; Kantarjian HM; Talpaz M; Estrov Z
    Int J Oncol; 2000 Dec; 17(6):1277-87. PubMed ID: 11078816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor heterogeneity makes AML a "moving target" for detection of residual disease.
    Zeijlemaker W; Gratama JW; Schuurhuis GJ
    Cytometry B Clin Cytom; 2014 Jan; 86(1):3-14. PubMed ID: 24151248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of polymerase chain reaction (PCR) in oncohematology. Detection of minimal residual disease].
    Kotliar N; Koziner B
    Medicina (B Aires); 1995; 55(2):159-66. PubMed ID: 7565055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of PCR technology for detecting minimal residual disease in patients with leukemia.
    Radich JP
    Rev Immunogenet; 1999; 1(2):265-78. PubMed ID: 11253952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction.
    Drexler HG; Borkhardt A; Janssen JW
    Leuk Lymphoma; 1995 Nov; 19(5-6):359-80. PubMed ID: 8590836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing minimal residual disease (MRD) in leukemia: a changing definition and concept?
    Paietta E
    Bone Marrow Transplant; 2002 Mar; 29(6):459-65. PubMed ID: 11960263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
    Chan DW; Liang R; Kwong YL; Chan V
    Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
    N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.
    Béné MC; Kaeda JS
    Haematologica; 2009 Aug; 94(8):1135-50. PubMed ID: 19586938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymerase chain reaction (PCR) approach for the evaluation of minimal residual disease in acute leukemia.
    Biondi A; Rambaldi A
    Stem Cells; 1994 Jul; 12(4):394-401. PubMed ID: 7951006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.
    Buckley SA; Wood BL; Othus M; Hourigan CS; Ustun C; Linden MA; DeFor TE; Malagola M; Anthias C; Valkova V; Kanakry CG; Gruhn B; Buccisano F; Devine B; Walter RB
    Haematologica; 2017 May; 102(5):865-873. PubMed ID: 28126965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.
    Oran B; Jorgensen JL; Marin D; Wang S; Ahmed S; Alousi AM; Andersson BS; Bashir Q; Bassett R; Lyons G; Chen J; Rezvani K; Popat U; Kebriaei P; Patel K; Rondon G; Shpall EJ; Champlin RE
    Haematologica; 2017 Jan; 102(1):110-117. PubMed ID: 27540139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction.
    van Dongen JJ; Breit TM; Adriaansen HJ; Beishuizen A; Hooijkaas H
    Leukemia; 1992; 6 Suppl 1():47-59. PubMed ID: 1548936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.